IDO2-IN-1
Based on 2 publication(s) in Google Scholar
IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor with an IC50 value of 112 nM. IDO2-IN-1 can be used for inflammatory autoimmunity research.
For research use only. We do not sell to patients.
- Purity: 98.10%
- CAS No.: 2803768-09-2
- Formula: C21H21BrN10O3
- Molecular Weight:541.36
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Orally Active Compound Library
HY-L061
-
Metabolic Enzyme Compound Library
HY-L146
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) IDO2-IN-1
More
Biological Activity
|
IDO1 411 nM (IC50) |
IDO2 112 (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | EC50 |
633 nM
Compound: 22
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 35952367] |
IDO2-IN-1 (compound 22) shows stronger inhibition on IDO2 (IC50 =112 nM) over IDO1 (IC50 =411 nM)[1].
IDO2-IN-1 inhibits hIDO1 expression (EC50=633 nM) in HeLa cell-based IDO1/kynurenine assay, co-incubated with hIFN-γ (100 ng/mL final concentration), which is used for producing N-formylkynurenine[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa cells line expressing hIDO1 induced by IFN-γ
-
Concentration:1 nM-0.1 mM
-
Incubation Time:48 hours
-
Result:Showed additional potency against IDO1 with an EC50 value of 633 nM.
IDO2-IN-1 (compound 22) (100 mg/kg; p.o.; once dose) exhibits excellent anti-inflammatory activity, higher than naproxen, a prescription drug reducing pain, swelling, and joint stiffness from arthritis[1].
IDO2-IN-1 (25, 50, 100 mg/kg; i.p.; once daily, for 19 d) exhibits excellent inhibitory effect on mice paw swelling, shows efficacy in a collagen-induced arthritis model in mice[1].
IDO2-IN-1 (30, 60, 120 mg/kg; i.p.; once daily, for 15 d) inhibits joint inflammation and displays potential effect in autoimmune arthritis improvement[1].
Pharmacokinetic Profile in Rat[1]
| Route | Dose (mg/kg) | T1/2/sub> (h) | Tmax (h) | Cmax (ng/mL) | AUC(0-∞) (h•ng/mL) | CL (mL/h/kg) | Vz (mL/kg) | MRT(0-∞) (h) | F (%) |
| i.v. | 1 | 0.69 | / | / | 375.1 | 2673 | 2675 | 0.55 | / |
| p.o. | 10 | 2.02 | 0.75 | 153.8 | 670.5 | / | / | 7.48 | 17.87 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Xylene-induced ear swelling mouse model (ICR mice, male, 6 weeks old)[1]
-
Dosage:100 mg/kg
-
Administration:Oral gavage; once dose; evenly coated right ear with 25 μL of xylene after 1 h treatment
-
Result:Significantly relieved mouse ear swelling with a high swelling inhibition rate of 65.32%.
-
Animal Model:Collagen-induced arthritis (CIA) mice model (DBA/1J mice, male, 6 weeks old)[1]
-
Dosage:25, 50, 100 mg/kg
-
Administration:Intraperitoneal injection; once daily; 19 days, began on day 56 after collagen induced
-
Result:Decreased the expression of inflammatory cytokines IL-18 and IL-33.
Reduced inflammation and cartilage and bone erosions symptoms.
-
Animal Model:Adjuvant arthritis (AA) rat model (Sprague-Dawley rats, male, 180 ± 20 g)[1]
-
Dosage:30, 60, 120 mg/kg
-
Administration:Intraperitoneal injection; once daily; 15 days, began on day 21 after chondrex induced
-
Result:Significantly reduced IL-6 and TNF-α levels.
Decreased synovial hyperplasia accompanied by inflammatory cell infiltration, pannus formation, and bone erosion of cartilage in a dose-dependent manner.
Chemical Information
-
CAS No. 2803768-09-2
-
Appearance Solid
-
Molecular Weight 541.36
-
Formula C21H21BrN10O3
-
Color Off-white to light yellow
-
SMILES
BrC1=CC=CC(CN/C(C2=NON=C2NCCN3C=C(N=N3)CNC(C4=NC=CC=C4)=O)=N\O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Fundam Res
Biodegradable nanoparticles-mediated targeted drug delivery achieves trans-spatial immunotherapy. [Abstract]2022 Nov 17;4(6):1639-1649. PMID: 39734540 -
Int Immunopharmacol
Doxorubicin promotes NK cell dysfunction and induces acute liver injury through kynurenine-AhR axis. [Abstract]2025 Apr 24:153:114489. PMID: 40112597
Solvent & Solubility
DMSO : 140 mg/mL (258.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8472 mL | 9.2360 mL | 18.4720 mL | 46.1800 mL |
| 5 mM | 0.3694 mL | 1.8472 mL | 3.6944 mL | 9.2360 mL | |
| 10 mM | 0.1847 mL | 0.9236 mL | 1.8472 mL | 4.6180 mL | |
| 15 mM | 0.1231 mL | 0.6157 mL | 1.2315 mL | 3.0787 mL | |
| 20 mM | 0.0924 mL | 0.4618 mL | 0.9236 mL | 2.3090 mL | |
| 25 mM | 0.0739 mL | 0.3694 mL | 0.7389 mL | 1.8472 mL | |
| 30 mM | 0.0616 mL | 0.3079 mL | 0.6157 mL | 1.5393 mL | |
| 40 mM | 0.0462 mL | 0.2309 mL | 0.4618 mL | 1.1545 mL | |
| 50 mM | 0.0369 mL | 0.1847 mL | 0.3694 mL | 0.9236 mL | |
| 60 mM | 0.0308 mL | 0.1539 mL | 0.3079 mL | 0.7697 mL | |
| 80 mM | 0.0231 mL | 0.1154 mL | 0.2309 mL | 0.5772 mL | |
| 100 mM | 0.0185 mL | 0.0924 mL | 0.1847 mL | 0.4618 mL |
IDO2-IN-1 Related Classifications
HY-151093 Related Classifications
Powered by Bioz
- IDO2-IN-1
- 2803768-09-2
- Indoleamine 2,3-Dioxygenase (IDO)
- immunotherapeutic avenues
- rheumatoid arthritis
- indoleamine 2,3-dioxygenase 2
- autoimmune diseases
- immunomodulatory enzyme
- inflammatory autoimmunity
- collagen-induced arthritis mice model
- adjuvant arthritis rat model
- pathogenic mediator
- cancer immunology
- neurodegenerative diseases
- and neurological
- Inhibitor
- inhibitor
- inhibit